Literature DB >> 8473493

In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial hypoalphalipoproteinemia.

P Roma1, R E Gregg, M S Meng, R Ronan, L A Zech, G Franceschini, C R Sirtori, H B Brewer.   

Abstract

Apo A-IMilano is a mutant form of apo A-I in which cysteine is substituted for arginine at amino acid 173. Subjects with apo A-IMilano are characterized by having low levels of plasma HDL cholesterol and apo A-I. To determine the kinetic etiology of the decreased plasma levels of the apo A-I in these individuals, normal and mutant apo A-I were isolated, radiolabeled with either 125I or 131I, and both types of apo A-I were simultaneously injected into two normal control subjects and two subjects heterozygous for apo A-IMilano. In the normal subjects, apo A-IMilano was catabolized more rapidly than the normal apo A-I (mean residence times of 5.11 d for normal apo A-I vs. 3.91 d for apo A-IMilano), clearly establishing that apo A-IMilano is kinetically abnormal and that it has a shortened residence time in plasma. In the two apo A-IMilano subjects, both types of apo A-I were catabolized more rapidly than normal (residence times ranging from 2.63 to 3.70 d) with normal total apo A-I production rates (mean of 10.3 vs. 10.4 mg/kg per d in the normal subjects). Therefore, in the subjects with apo A-IMilano, the decreased apo A-I levels are caused by rapid catabolism of apo A-I and not to a decreased production rate, and the abnormal apo A-IMilano leads to the rapid catabolism of both the normal and mutant forms of apo A-I in the affected subjects.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8473493      PMCID: PMC288119          DOI: 10.1172/JCI116349

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Apolipoprotein A-IMilano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I.

Authors:  K H Weisgraber; S C Rall; T P Bersot; R W Mahley; G Franceschini; C R Sirtori
Journal:  J Biol Chem       Date:  1983-02-25       Impact factor: 5.157

2.  Discriminative value of lipids and apoproteins in coronary heart disease.

Authors:  G De Backer; M Rosseneu; J P Deslypere
Journal:  Atherosclerosis       Date:  1982-04       Impact factor: 5.162

3.  High density lipoprotein-3 heterogeneity in subjects with the apo-AIMilano variant.

Authors:  G Franceschini; T G Frosi; C Manzoni; G Gianfranceschi; C R Sirtori
Journal:  J Biol Chem       Date:  1982-09-10       Impact factor: 5.157

4.  Specific high-affinity binding of high density lipoproteins to cultured human skin fibroblasts and arterial smooth muscle cells.

Authors:  R Biesbroeck; J F Oram; J J Albers; E L Bierman
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

5.  Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol.

Authors:  G R Warnick; J Benderson; J J Albers
Journal:  Clin Chem       Date:  1982-06       Impact factor: 8.327

6.  Familial hypo-alpha-lipoproteinemia.

Authors:  C Vergani; G Bettale
Journal:  Clin Chim Acta       Date:  1981-07-18       Impact factor: 3.786

7.  Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease.

Authors:  J J Maciejko; D R Holmes; B A Kottke; A R Zinsmeister; D M Dinh; S J Mao
Journal:  N Engl J Med       Date:  1983-08-18       Impact factor: 91.245

8.  A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family.

Authors:  G Franceschini; C R Sirtori; A Capurso; K H Weisgraber; R W Mahley
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

9.  Human apolipoprotein A-I and A-II metabolism.

Authors:  E J Schaefer; L A Zech; L L Jenkins; T J Bronzert; E A Rubalcaba; F T Lindgren; R L Aamodt; H B Brewer
Journal:  J Lipid Res       Date:  1982-08       Impact factor: 5.922

10.  A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins.

Authors:  K H Weisgraber; T P Bersot; R W Mahley; G Franceschini; C R Sirtori
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

View more
  15 in total

1.  A model structure for the heterodimer apoA-IMilano-apoA-II supports its peculiar susceptibility to proteolysis.

Authors:  Alessandro Guerini Rocco; Luca Mollica; Elisabetta Gianazza; Laura Calabresi; Guido Franceschini; Cesare R Sirtori; Ivano Eberini
Journal:  Biophys J       Date:  2006-08-04       Impact factor: 4.033

Review 2.  HDL therapy today: from atherosclerosis, to stent compatibility to heart failure.

Authors:  C R Sirtori; M Ruscica; L Calabresi; G Chiesa; R Giovannoni; J J Badimon
Journal:  Ann Med       Date:  2019 Nov - Dec       Impact factor: 4.709

3.  Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys.

Authors:  Herman J Kempen; Monica Gomaraschi; S Eralp Bellibas; Stephanie Plassmann; Brad Zerler; Heidi L Collins; Steven J Adelman; Laura Calabresi; Peter L J Wijngaard
Journal:  J Lipid Res       Date:  2013-07-04       Impact factor: 5.922

Review 4.  Human genetics of variation in high-density lipoprotein cholesterol.

Authors:  Atif Qasim; Daniel J Rader
Journal:  Curr Atheroscler Rep       Date:  2006-05       Impact factor: 5.113

Review 5.  Apolipoproteins in vascular biology and atherosclerotic disease.

Authors:  Anurag Mehta; Michael D Shapiro
Journal:  Nat Rev Cardiol       Date:  2021-10-08       Impact factor: 32.419

Review 6.  High-density lipoprotein mimetics: promises and challenges.

Authors:  Dmitri Sviridov; Alan T Remaley
Journal:  Biochem J       Date:  2015-12-15       Impact factor: 3.857

Review 7.  ApoA-I-Directed Therapies for the Management of Atherosclerosis.

Authors:  John S Millar; Marina Cuchel
Journal:  Curr Atheroscler Rep       Date:  2015-10       Impact factor: 5.113

8.  Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I.

Authors:  Eric T Alexander; Masafumi Tanaka; Momoe Kono; Hiroyuki Saito; Daniel J Rader; Michael C Phillips
Journal:  J Lipid Res       Date:  2009-03-24       Impact factor: 5.922

Review 9.  Structural basis for distinct functions of the naturally occurring Cys mutants of human apolipoprotein A-I.

Authors:  Olga Gursky; Martin K Jones; Xiaohu Mei; Jere P Segrest; David Atkinson
Journal:  J Lipid Res       Date:  2013-09-13       Impact factor: 5.922

10.  Wild-type apo A-I and apo A-I(Milano) gene transfer reduce native and transplant arteriosclerosis to a similar extent.

Authors:  Yingmei Feng; Eline Van Craeyveld; Frank Jacobs; Joke Lievens; Jan Snoeys; Bart De Geest
Journal:  J Mol Med (Berl)       Date:  2008-12-10       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.